25 XP   0   0   10

Samil Pharm
Buy, Hold or Sell?

Let's analyse Samil Pharm together

PenkeI guess you are interested in Samil Pharm. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Samil Pharm. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Samil Pharm

I send you an email if I find something interesting about Samil Pharm.

Quick analysis of Samil Pharm (30 sec.)










What can you expect buying and holding a share of Samil Pharm? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
77.5%

What is your share worth?

Current worth
₩7,716.06
Expected worth in 1 year
₩7,837.26
How sure are you?
62.5%

+ What do you gain per year?

Total Gains per Share
₩121.20
Return On Investment
1.3%

For what price can you sell your share?

Current Price per Share
₩9,260.00
Expected price per share
₩7,180 - ₩12,650
How sure are you?
50%

1. Valuation of Samil Pharm (5 min.)




Live pricePrice per Share (EOD)

₩9,260.00

Intrinsic Value Per Share

₩12,235.86 - ₩15,529.30

Total Value Per Share

₩19,951.92 - ₩23,245.37

2. Growth of Samil Pharm (5 min.)




Is Samil Pharm growing?

Current yearPrevious yearGrowGrow %
How rich?$89.4m$59.5m$31.9m34.9%

How much money is Samil Pharm making?

Current yearPrevious yearGrowGrow %
Making money$291.1k-$4.9k$296k101.7%
Net Profit Margin0.9%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Samil Pharm (5 min.)




What can you expect buying and holding a share of Samil Pharm? (5 min.)

Welcome investor! Samil Pharm's management wants to use your money to grow the business. In return you get a share of Samil Pharm.

What can you expect buying and holding a share of Samil Pharm?

First you should know what it really means to hold a share of Samil Pharm. And how you can make/lose money.

Speculation

The Price per Share of Samil Pharm is ₩9,260. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Samil Pharm.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Samil Pharm, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩7,716.06. Based on the TTM, the Book Value Change Per Share is ₩30.30 per quarter. Based on the YOY, the Book Value Change Per Share is ₩906.55 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Samil Pharm.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.040.0%0.020.0%0.000.0%0.000.0%-0.010.0%
Usd Book Value Change Per Share-0.210.0%0.020.0%0.630.0%0.150.0%0.060.0%
Usd Dividend Per Share0.000.0%0.000.0%0.020.0%0.020.0%0.030.0%
Usd Total Gains Per Share-0.210.0%0.020.0%0.660.0%0.170.0%0.090.0%
Usd Price Per Share4.69-5.02-5.30-9.32-8.41-
Price to Earnings Ratio31.03-18.48--1.75--9.46-6.09-
Price-to-Total Gains Ratio-22.85--96.44-45.74--62.23-1.56-
Price to Book Ratio0.87-0.91-1.57-3.25-3.28-
Price-to-Total Gains Ratio-22.85--96.44-45.74--62.23-1.56-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share6.482
Number of shares154
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.02
Usd Book Value Change Per Share0.020.15
Usd Total Gains Per Share0.020.17
Gains per Quarter (154 shares)3.2726.39
Gains per Year (154 shares)13.06105.55
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10133129396
20261624187202
30392937280308
40524249373414
50655561467520
60786873560626
70918185654732
801059497747838
90118107110840944
1001311201229341050

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%6.06.00.050.0%10.010.00.050.0%18.016.06.045.0%20.016.08.045.5%
Book Value Change Per Share2.02.00.050.0%8.04.00.066.7%12.08.00.060.0%16.024.00.040.0%18.026.00.040.9%
Dividend per Share0.00.04.00.0%8.00.04.066.7%12.00.08.060.0%31.00.09.077.5%33.00.011.075.0%
Total Gains per Share2.02.00.050.0%9.03.00.075.0%14.06.00.070.0%25.015.00.062.5%28.016.00.063.6%

Fundamentals of Samil Pharm

About Samil Pharm

Samil Pharmaceutical Co.,Ltd engages in the manufacture and sale of indispensable medicines in South Korea. It offers hepatic, gastrointestinal, vasodilator, antithrombotic, respiratory, skeletal muscle relaxants, circulatory, neurological, antibiotics, metabolic, antihistamines, immunosuppressive, hormone, anti-tumor, urinary, and ophthalmic drugs, as well as antipyretic, analgesic, and anti-inflammatory agents. The company also provides OTC products and sanitary aids. Samil Pharmaceutical Co.,Ltd was founded in 1947 and is headquartered in Seoul, South Korea.

Fundamental data was last updated by Penke on 2024-04-13 16:43:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is not making a profit/loss.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Samil Pharm.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Samil Pharm earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Samil Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 1.8% means that ₩0.02 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Samil Pharm:

  • The MRQ is 1.8%. The company is making a profit. +1
  • The TTM is 0.9%. The company is not making a profit/loss.
Trends
Current periodCompared to+/- 
MRQ1.8%TTM0.9%+0.9%
TTM0.9%YOY0.0%+0.9%
TTM0.9%5Y-0.3%+1.1%
5Y-0.3%10Y-1.0%+0.7%
1.1.2. Return on Assets

Shows how efficient Samil Pharm is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Samil Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.2% Return on Assets means that Samil Pharm generated ₩0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Samil Pharm:

  • The MRQ is 0.2%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.1%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.2%TTM0.1%+0.1%
TTM0.1%YOY0.0%+0.1%
TTM0.1%5Y0.0%+0.1%
5Y0.0%10Y-0.1%+0.1%
1.1.3. Return on Equity

Shows how efficient Samil Pharm is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Samil Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.7% Return on Equity means Samil Pharm generated ₩0.01 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Samil Pharm:

  • The MRQ is 0.7%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 0.3%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.7%TTM0.3%+0.4%
TTM0.3%YOY-0.2%+0.5%
TTM0.3%5Y-0.2%+0.5%
5Y-0.2%10Y-0.5%+0.3%

1.2. Operating Efficiency of Samil Pharm.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Samil Pharm is operating .

  • Measures how much profit Samil Pharm makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Samil Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Samil Pharm:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY2.2%-2.2%
TTM-5Y3.3%-3.3%
5Y3.3%10Y1.3%+2.0%
1.2.2. Operating Ratio

Measures how efficient Samil Pharm is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.56 means that the operating costs are ₩1.56 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Samil Pharm:

  • The MRQ is 1.561. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.589. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.561TTM1.589-0.028
TTM1.589YOY1.603-0.013
TTM1.5895Y1.555+0.034
5Y1.55510Y1.294+0.261

1.3. Liquidity of Samil Pharm.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Samil Pharm is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 0.48 means the company has ₩0.48 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Samil Pharm:

  • The MRQ is 0.481. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.514. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.481TTM0.514-0.033
TTM0.514YOY0.616-0.102
TTM0.5145Y0.763-0.249
5Y0.76310Y0.600+0.163
1.3.2. Quick Ratio

Measures if Samil Pharm is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Samil Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.21 means the company can pay off ₩0.21 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Samil Pharm:

  • The MRQ is 0.212. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.219. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.212TTM0.219-0.007
TTM0.219YOY0.289-0.070
TTM0.2195Y0.362-0.143
5Y0.36210Y0.562-0.199

1.4. Solvency of Samil Pharm.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Samil Pharm assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Samil Pharm to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.66 means that Samil Pharm assets are financed with 65.5% credit (debt) and the remaining percentage (100% - 65.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Samil Pharm:

  • The MRQ is 0.655. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.648. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.655TTM0.648+0.007
TTM0.648YOY0.712-0.063
TTM0.6485Y0.669-0.021
5Y0.66910Y0.594+0.075
1.4.2. Debt to Equity Ratio

Measures if Samil Pharm is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Samil Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 190.0% means that company has ₩1.90 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Samil Pharm:

  • The MRQ is 1.900. The company is just able to pay all its debts with equity.
  • The TTM is 1.843. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.900TTM1.843+0.057
TTM1.843YOY2.519-0.676
TTM1.8435Y2.058-0.215
5Y2.05810Y1.600+0.458

2. Market Valuation of Samil Pharm

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Samil Pharm generates.

  • Above 15 is considered overpriced but always compare Samil Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 31.03 means the investor is paying ₩31.03 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Samil Pharm:

  • The EOD is 42.893. Based on the earnings, the company is overpriced. -1
  • The MRQ is 31.035. Based on the earnings, the company is overpriced. -1
  • The TTM is 18.479. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD42.893MRQ31.035+11.858
MRQ31.035TTM18.479+12.556
TTM18.479YOY-1.747+20.226
TTM18.4795Y-9.460+27.939
5Y-9.46010Y6.095-15.555
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Samil Pharm:

  • The EOD is 7.319. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 5.296. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is -17.715. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD7.319MRQ5.296+2.023
MRQ5.296TTM-17.715+23.011
TTM-17.715YOY-10.931-6.785
TTM-17.7155Y-9.992-7.723
5Y-9.99210Y-4.745-5.247
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Samil Pharm is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 0.87 means the investor is paying ₩0.87 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Samil Pharm:

  • The EOD is 1.200. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.868. Based on the equity, the company is cheap. +2
  • The TTM is 0.909. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.200MRQ0.868+0.332
MRQ0.868TTM0.909-0.040
TTM0.909YOY1.568-0.659
TTM0.9095Y3.249-2.341
5Y3.24910Y3.280-0.030
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Samil Pharm compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---293.27230.299-1068%906.550-132%216.536-235%87.225-436%
Book Value Per Share--7716.0627888.951-2%5135.391+50%4916.000+57%4118.792+87%
Current Ratio--0.4810.514-6%0.616-22%0.763-37%0.600-20%
Debt To Asset Ratio--0.6550.648+1%0.712-8%0.669-2%0.594+10%
Debt To Equity Ratio--1.9001.843+3%2.519-25%2.058-8%1.600+19%
Dividend Per Share----0%31.316-100%28.254-100%38.169-100%
Eps--53.97125.104+115%-0.427+101%-4.783+109%-14.149+126%
Free Cash Flow Per Share--316.301-190.824+160%-671.575+312%-308.299+197%-382.725+221%
Free Cash Flow To Equity Per Share--316.301-190.824+160%-223.285+171%-44.751+114%-32.632+110%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.850+18%
Intrinsic Value_10Y_max--15529.303--------
Intrinsic Value_10Y_min--12235.863--------
Intrinsic Value_1Y_max---1305.039--------
Intrinsic Value_1Y_min---1283.547--------
Intrinsic Value_3Y_max---1740.561--------
Intrinsic Value_3Y_min---1705.704--------
Intrinsic Value_5Y_max--452.791--------
Intrinsic Value_5Y_min--232.594--------
Market Cap153404864000.000+28%110994880000.000118822504000.000-7%125339878170.880-11%220467912679.264-50%199131528667.760-44%
Net Profit Margin--0.0180.009+101%0.000+6700%-0.003+115%-0.010+155%
Operating Margin----0%0.022-100%0.033-100%0.013-100%
Operating Ratio--1.5611.589-2%1.603-3%1.555+0%1.294+21%
Pb Ratio1.200+28%0.8680.909-4%1.568-45%3.249-73%3.280-74%
Pe Ratio42.893+28%31.03518.479+68%-1.747+106%-9.460+130%6.095+409%
Price Per Share9260.000+28%6700.0007172.500-7%7565.909-11%13308.137-50%12020.205-44%
Price To Free Cash Flow Ratio7.319+28%5.296-17.715+435%-10.931+306%-9.992+289%-4.745+190%
Price To Total Gains Ratio-31.575-38%-22.846-96.438+322%45.744-150%-62.231+172%1.563-1562%
Quick Ratio--0.2120.219-3%0.289-27%0.362-41%0.562-62%
Return On Assets--0.0020.001+110%0.000+112%0.000+110%-0.001+154%
Return On Equity--0.0070.003+117%-0.002+131%-0.002+126%-0.005+166%
Total Gains Per Share---293.27230.299-1068%937.866-131%244.790-220%125.395-334%
Usd Book Value--89479160.24691484060.183-2%59552456.822+50%57008290.059+57%47763494.694+87%
Usd Book Value Change Per Share---0.2050.021-1068%0.635-132%0.152-235%0.061-436%
Usd Book Value Per Share--5.4015.522-2%3.595+50%3.441+57%2.883+87%
Usd Dividend Per Share----0%0.022-100%0.020-100%0.027-100%
Usd Eps--0.0380.018+115%0.000+101%-0.003+109%-0.010+126%
Usd Free Cash Flow--3667976.396-2212889.245+160%-7787908.863+312%-3575181.818+197%-3772527.036+203%
Usd Free Cash Flow Per Share--0.221-0.134+160%-0.470+312%-0.216+197%-0.268+221%
Usd Free Cash Flow To Equity Per Share--0.221-0.134+160%-0.156+171%-0.031+114%-0.023+110%
Usd Market Cap107383404.800+28%77696416.00083175752.800-7%87737914.720-11%154327538.875-50%139392070.067-44%
Usd Price Per Share6.482+28%4.6905.021-7%5.296-11%9.316-50%8.414-44%
Usd Profit--625878.008291119.416+115%-4950.227+101%-55460.605+109%-164077.378+126%
Usd Revenue--35360878.90334360516.372+3%31443318.944+12%26403117.010+34%21198933.891+67%
Usd Total Gains Per Share---0.2050.021-1068%0.657-131%0.171-220%0.088-334%
 EOD+3 -5MRQTTM+16 -16YOY+20 -155Y+20 -1510Y+18 -18

3.2. Fundamental Score

Let's check the fundamental score of Samil Pharm based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1542.893
Price to Book Ratio (EOD)Between0-11.200
Net Profit Margin (MRQ)Greater than00.018
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.212
Current Ratio (MRQ)Greater than10.481
Debt to Asset Ratio (MRQ)Less than10.655
Debt to Equity Ratio (MRQ)Less than11.900
Return on Equity (MRQ)Greater than0.150.007
Return on Assets (MRQ)Greater than0.050.002
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of Samil Pharm based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.753
Ma 20Greater thanMa 5010,260.000
Ma 50Greater thanMa 1009,660.600
Ma 100Greater thanMa 2008,607.200
OpenGreater thanClose9,260.000
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets370,680,097
Total Liabilities242,852,725
Total Stockholder Equity127,827,372
 As reported
Total Liabilities 242,852,725
Total Stockholder Equity+ 127,827,372
Total Assets = 370,680,097

Assets

Total Assets370,680,097
Total Current Assets81,115,093
Long-term Assets289,565,004
Total Current Assets
Cash And Cash Equivalents 906,143
Net Receivables 35,813,441
Inventory 32,511,412
Other Current Assets 11,718,167
Total Current Assets  (as reported)81,115,093
Total Current Assets  (calculated)80,949,162
+/- 165,931
Long-term Assets
Property Plant Equipment 242,198,496
Intangible Assets 2,818,624
Long-term Assets Other 798,872
Long-term Assets  (as reported)289,565,004
Long-term Assets  (calculated)245,815,993
+/- 43,749,011

Liabilities & Shareholders' Equity

Total Current Liabilities168,674,682
Long-term Liabilities74,178,044
Total Stockholder Equity127,827,372
Total Current Liabilities
Short Long Term Debt 124,698,137
Accounts payable 21,003,672
Other Current Liabilities 3,146,286
Total Current Liabilities  (as reported)168,674,682
Total Current Liabilities  (calculated)148,848,095
+/- 19,826,587
Long-term Liabilities
Long term Debt 49,568,462
Capital Lease Obligations Min Short Term Debt1,612,554
Long-term Liabilities Other 1
Long-term Liabilities  (as reported)74,178,044
Long-term Liabilities  (calculated)51,181,016
+/- 22,997,027
Total Stockholder Equity
Retained Earnings 28,018,582
Total Stockholder Equity (as reported)127,827,372
Total Stockholder Equity (calculated)28,018,582
+/- 99,808,790
Other
Capital Stock7,613,393
Common Stock Shares Outstanding 14,462
Net Debt 173,360,456
Net Invested Capital 302,093,971
Net Working Capital -87,559,588
Property Plant and Equipment Gross 297,606,794



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-31
> Total Assets 
109,104,288
107,978,146
107,220,015
115,708,901
116,402,983
114,610,286
113,227,133
108,291,024
108,474,587
105,420,727
99,730,282
99,311,888
98,239,697
101,195,193
102,948,685
100,995,489
96,612,188
130,281,985
132,312,053
135,477,089
134,581,074
136,773,674
150,979,964
147,948,619
147,338,375
148,707,422
183,171,422
183,874,717
181,857,115
184,369,992
187,068,355
191,660,927
195,389,979
227,733,156
230,479,273
226,404,983
241,939,218
272,837,676
288,863,963
356,700,497
359,895,869
372,368,195
383,180,124
370,680,097
370,680,097383,180,124372,368,195359,895,869356,700,497288,863,963272,837,676241,939,218226,404,983230,479,273227,733,156195,389,979191,660,927187,068,355184,369,992181,857,115183,874,717183,171,422148,707,422147,338,375147,948,619150,979,964136,773,674134,581,074135,477,089132,312,053130,281,98596,612,188100,995,489102,948,685101,195,19398,239,69799,311,88899,730,282105,420,727108,474,587108,291,024113,227,133114,610,286116,402,983115,708,901107,220,015107,978,146109,104,288
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
55,958,110
53,098,632
47,555,450
48,617,764
52,160,166
51,670,437
51,848,816
63,900,087
59,184,330
61,785,982
50,516,607
87,898,241
79,199,814
77,234,249
71,584,478
73,728,300
72,523,350
69,968,283
94,324,307
87,731,587
76,710,526
80,258,948
81,424,121
76,589,678
74,781,467
75,591,548
84,762,176
91,632,384
81,115,093
81,115,09391,632,38484,762,17675,591,54874,781,46776,589,67881,424,12180,258,94876,710,52687,731,58794,324,30769,968,28372,523,35073,728,30071,584,47877,234,24979,199,81487,898,24150,516,60761,785,98259,184,33063,900,08751,848,81651,670,43752,160,16648,617,76447,555,45053,098,63255,958,110000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,167,105
4,021,539
3,545,306
2,269,179
991,233
2,130,255
2,460,653
5,206,808
2,989,349
5,757,448
3,116,064
31,051,288
16,718,390
17,189,334
9,971,041
9,311,116
15,997,146
10,262,516
18,686,143
17,448,488
3,991,990
11,155,077
10,693,524
1,943,141
1,903,467
3,046,468
1,985,350
9,600,660
906,143
906,1439,600,6601,985,3503,046,4681,903,4671,943,14110,693,52411,155,0773,991,99017,448,48818,686,14310,262,51615,997,1469,311,1169,971,04117,189,33416,718,39031,051,2883,116,0645,757,4482,989,3495,206,8082,460,6532,130,255991,2332,269,1793,545,3064,021,5396,167,105000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,000,000
2,000,000
0
0
0
0
0
8,000,000
8,000,000
0
0
0
13,031,796
11,065,991
12,072,730
12,078,322
1,200,000
1,200,000
16,200,000
11,000,000
11,268,646
268,646
221,795
5,795
0
0
0
0
0
000005,795221,795268,64611,268,64611,000,00016,200,0001,200,0001,200,00012,078,32212,072,73011,065,99113,031,7960008,000,0008,000,000000002,000,0002,000,000000000000000000
       Net Receivables 
33,271,338
33,297,438
32,683,230
33,308,060
37,008,730
37,954,078
38,907,378
34,050,570
36,174,689
35,547,465
36,882,464
35,612,784
36,287,067
35,419,446
32,794,826
34,868,588
33,757,060
29,455,471
30,439,038
32,926,973
29,232,522
30,037,826
27,575,255
23,444,840
25,989,929
25,691,232
26,401,363
26,271,870
26,942,344
27,005,245
29,429,437
30,195,039
33,193,660
33,877,682
32,862,455
31,132,642
37,684,060
37,002,928
37,404,918
34,304,444
34,270,770
34,480,356
37,741,374
35,813,441
35,813,44137,741,37434,480,35634,270,77034,304,44437,404,91837,002,92837,684,06031,132,64232,862,45533,877,68233,193,66030,195,03929,429,43727,005,24526,942,34426,271,87026,401,36325,691,23225,989,92923,444,84027,575,25530,037,82629,232,52232,926,97330,439,03829,455,47133,757,06034,868,58832,794,82635,419,44636,287,06735,612,78436,882,46435,547,46536,174,68934,050,57038,907,37837,954,07837,008,73033,308,06032,683,23033,297,43833,271,338
       Other Current Assets 
891,710
831,911
432,311
514,620
457,795
521,594
399,505
690,140
270,303
606,425
243,925
418,676
488,897
491,874
2,323,170
1,584,744
3,410,153
1,966,809
950,474
1,775,964
3,191,781
418,115
894,098
615,517
994
50,990
73,030
434,109
555,670
585,001
704,009
279,556
719,761
770,204
1,197,111
2,986,603
4,971,400
3,031,523
1,835,390
13,831,572
92,414
3,784
23,666
11,718,167
11,718,16723,6663,78492,41413,831,5721,835,3903,031,5234,971,4002,986,6031,197,111770,204719,761279,556704,009585,001555,670434,10973,03050,990994615,517894,098418,1153,191,7811,775,964950,4741,966,8093,410,1531,584,7442,323,170491,874488,897418,676243,925606,425270,303690,140399,505521,594457,795514,620432,311831,911891,710
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
85,552,393
98,190,815
95,273,181
104,674,903
104,622,866
112,785,514
113,340,055
119,137,577
125,421,696
133,408,850
142,747,686
149,694,457
161,680,270
191,413,554
212,274,285
281,919,029
284,304,322
287,606,019
291,547,740
289,565,004
289,565,004291,547,740287,606,019284,304,322281,919,029212,274,285191,413,554161,680,270149,694,457142,747,686133,408,850125,421,696119,137,577113,340,055112,785,514104,622,866104,674,90395,273,18198,190,81585,552,393000000000000000000000000
       Property Plant Equipment 
35,561,889
35,004,897
35,086,806
35,258,054
35,425,538
37,421,806
38,031,103
39,415,711
38,766,268
38,320,496
38,545,805
38,449,711
38,238,462
38,539,741
39,088,087
39,214,784
39,121,768
71,725,666
72,149,605
71,892,903
71,302,774
71,193,214
67,192,991
62,348,976
63,071,427
63,646,264
62,398,630
71,901,750
72,311,911
80,859,935
81,143,220
64,807,824
72,335,380
75,681,373
79,864,048
103,393,597
115,670,235
144,010,839
163,681,825
233,945,736
236,785,514
239,611,165
243,634,309
242,198,496
242,198,496243,634,309239,611,165236,785,514233,945,736163,681,825144,010,839115,670,235103,393,59779,864,04875,681,37372,335,38064,807,82481,143,22080,859,93572,311,91171,901,75062,398,63063,646,26463,071,42762,348,97667,192,99171,193,21471,302,77471,892,90372,149,60571,725,66639,121,76839,214,78439,088,08738,539,74138,238,46238,449,71138,545,80538,320,49638,766,26839,415,71138,031,10337,421,80635,425,53835,258,05435,086,80635,004,89735,561,889
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,086,500
956,000
956,000
998,000
1,010,000
1,019,000
1,028,000
1,073,001
1,884,804
878,332
805,364
778,396
1,025,400
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000001,025,400778,396805,364878,3321,884,8041,073,0011,028,0001,019,0001,010,000998,000956,000956,0001,086,500000000000000000
       Intangible Assets 
6,054,665
5,917,787
5,198,208
5,050,678
5,175,057
5,180,581
5,062,918
1,996,945
2,205,099
2,131,070
2,070,316
2,007,731
1,966,747
1,906,304
1,846,153
2,054,883
1,661,071
1,542,648
1,625,203
1,566,717
1,704,150
1,638,418
1,634,017
1,571,501
1,823,957
1,809,143
1,773,009
1,731,128
1,686,142
1,638,558
1,765,363
1,726,024
1,945,154
1,980,458
1,430,352
1,295,171
1,367,239
1,321,371
1,276,576
3,136,477
3,049,201
2,969,068
2,926,698
2,818,624
2,818,6242,926,6982,969,0683,049,2013,136,4771,276,5761,321,3711,367,2391,295,1711,430,3521,980,4581,945,1541,726,0241,765,3631,638,5581,686,1421,731,1281,773,0091,809,1431,823,9571,571,5011,634,0171,638,4181,704,1501,566,7171,625,2031,542,6481,661,0712,054,8831,846,1531,906,3041,966,7472,007,7312,070,3162,131,0702,205,0991,996,9455,062,9185,180,5815,175,0575,050,6785,198,2085,917,7876,054,665
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
647,021
647,022
665,022
665,022
665,022
772,454
921,055
1,170,995
1,170,994
1,170,995
1,243,659
1,243,659
899,854
798,872
798,873
159,742
159,744
-1,297,533
798,871
798,872
798,872798,871-1,297,533159,744159,742798,873798,872899,8541,243,6591,243,6591,170,9951,170,9941,170,995921,055772,454665,022665,022665,022647,022647,021000000000000000000000000
> Total Liabilities 
46,695,039
45,860,004
45,681,602
45,681,965
47,557,635
50,469,264
52,061,298
52,875,901
53,076,849
50,512,884
44,669,863
44,901,633
44,566,127
47,775,306
49,223,941
48,124,700
43,924,501
77,904,192
81,950,018
84,309,810
86,355,929
90,621,898
90,532,984
91,865,621
90,690,904
91,016,540
118,821,272
121,602,282
119,783,038
122,427,193
121,155,415
128,109,718
131,256,523
158,341,523
158,450,343
160,658,491
176,278,925
202,267,496
210,614,278
230,880,901
230,597,001
239,414,208
250,494,293
242,852,725
242,852,725250,494,293239,414,208230,597,001230,880,901210,614,278202,267,496176,278,925160,658,491158,450,343158,341,523131,256,523128,109,718121,155,415122,427,193119,783,038121,602,282118,821,27291,016,54090,690,90491,865,62190,532,98490,621,89886,355,92984,309,81081,950,01877,904,19243,924,50148,124,70049,223,94147,775,30644,566,12744,901,63344,669,86350,512,88453,076,84952,875,90152,061,29850,469,26447,557,63545,681,96545,681,60245,860,00446,695,039
   > Total Current Liabilities 
35,649,666
34,735,898
34,287,426
42,785,732
42,317,214
45,660,055
47,137,140
41,143,968
40,621,321
25,648,724
39,176,286
41,624,305
40,870,821
44,828,747
44,672,648
43,190,577
38,568,874
44,651,777
48,994,173
52,411,973
54,207,027
84,013,925
85,475,315
85,319,898
83,651,327
83,592,203
83,560,515
68,155,719
64,416,175
67,241,960
70,278,080
98,683,674
101,268,386
101,210,998
99,718,967
121,674,245
103,834,699
139,887,601
140,377,308
132,592,029
157,469,080
162,748,577
159,911,027
168,674,682
168,674,682159,911,027162,748,577157,469,080132,592,029140,377,308139,887,601103,834,699121,674,24599,718,967101,210,998101,268,38698,683,67470,278,08067,241,96064,416,17568,155,71983,560,51583,592,20383,651,32785,319,89885,475,31584,013,92554,207,02752,411,97348,994,17344,651,77738,568,87443,190,57744,672,64844,828,74740,870,82141,624,30539,176,28625,648,72440,621,32141,143,96847,137,14045,660,05542,317,21442,785,73234,287,42634,735,89835,649,666
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,200,000
30,200,000
59,200,000
60,200,000
61,200,000
66,200,000
68,208,464
0
0
64,700,000
64,908,520
64,811,228
48,045,020
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000048,045,02064,811,22864,908,52064,700,0000068,208,46466,200,00061,200,00060,200,00059,200,00030,200,00030,200,000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,200,000
30,200,000
59,200,000
60,200,000
61,200,000
66,200,000
68,208,464
0
0
64,700,000
64,908,520
64,811,228
48,045,020
45,600,400
46,600,400
50,212,375
73,772,519
76,850,411
77,477,599
76,040,176
92,292,790
72,480,000
98,217,264
100,317,315
85,501,530
112,181,737
109,580,000
115,024,284
124,698,137
124,698,137115,024,284109,580,000112,181,73785,501,530100,317,31598,217,26472,480,00092,292,79076,040,17677,477,59976,850,41173,772,51950,212,37546,600,40045,600,40048,045,02064,811,22864,908,52064,700,0000068,208,46466,200,00061,200,00060,200,00059,200,00030,200,00030,200,000000000000000000
       Accounts payable 
5,010,289
6,078,219
4,889,050
5,973,434
5,222,057
5,320,254
3,839,864
5,922,081
5,307,084
5,860,725
5,171,135
6,123,116
5,166,228
5,105,055
5,963,721
5,965,266
2,855,239
5,162,978
7,435,810
9,013,990
5,963,319
7,674,788
8,569,254
9,235,647
7,480,213
8,171,151
8,493,784
9,129,708
6,748,651
7,213,361
7,381,262
10,825,842
9,082,313
9,913,735
9,723,161
8,541,358
12,061,507
14,304,434
13,298,034
13,660,103
11,407,219
27,072,598
23,605,042
21,003,672
21,003,67223,605,04227,072,59811,407,21913,660,10313,298,03414,304,43412,061,5078,541,3589,723,1619,913,7359,082,31310,825,8427,381,2627,213,3616,748,6519,129,7088,493,7848,171,1517,480,2139,235,6478,569,2547,674,7885,963,3199,013,9907,435,8105,162,9782,855,2395,965,2665,963,7215,105,0555,166,2286,123,1165,171,1355,860,7255,307,0845,922,0813,839,8645,320,2545,222,0575,973,4344,889,0506,078,2195,010,289
       Other Current Liabilities 
8,639,377
6,657,679
7,398,376
10,812,298
12,095,157
9,839,801
9,797,276
7,021,887
7,414,237
6,087,999
6,305,151
7,301,189
7,504,593
8,523,692
8,508,927
9,025,311
7,513,635
7,288,799
8,358,363
9,197,983
9,043,708
7,664,495
8,057,474
7,157,104
2,875,293
3,040,746
3,150,567
7,846,217
9,100,520
9,642,395
9,351,263
9,920,271
11,285,403
9,170,484
8,977,147
16,780,498
15,190,042
22,782,845
10,880,261
28,964,584
3,024,053
3,013,709
3,007,928
3,146,286
3,146,2863,007,9283,013,7093,024,05328,964,58410,880,26122,782,84515,190,04216,780,4988,977,1479,170,48411,285,4039,920,2719,351,2639,642,3959,100,5207,846,2173,150,5673,040,7462,875,2937,157,1048,057,4747,664,4959,043,7089,197,9838,358,3637,288,7997,513,6359,025,3118,508,9278,523,6927,504,5937,301,1896,305,1516,087,9997,414,2377,021,8879,797,2769,839,80112,095,15710,812,2987,398,3766,657,6798,639,377
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,039,578
7,424,337
35,260,757
53,446,563
55,366,863
55,185,233
50,877,335
29,426,044
29,988,137
57,130,525
58,731,376
38,984,246
72,444,226
62,379,895
70,236,969
98,288,872
73,127,921
76,665,632
90,583,267
74,178,044
74,178,04490,583,26776,665,63273,127,92198,288,87270,236,96962,379,89572,444,22638,984,24658,731,37657,130,52529,988,13729,426,04450,877,33555,185,23355,366,86353,446,56335,260,7577,424,3377,039,578000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-30,200,000
-30,200,000
-59,200,000
-60,200,000
-61,200,000
-66,200,000
-68,208,464
0
0
-64,301,393
-64,571,239
-64,567,267
-47,452,511
572,855
791,266
735,156
629,986
617,727
674,987
557,398
1,311,612
1,477,101
1,745,218
1,826,258
1,839,418
1,844,377
1,826,732
1,771,871
1,612,554
1,612,5541,771,8711,826,7321,844,3771,839,4181,826,2581,745,2181,477,1011,311,612557,398674,987617,727629,986735,156791,266572,855-47,452,511-64,567,267-64,571,239-64,301,39300-68,208,464-66,200,000-61,200,000-60,200,000-59,200,000-30,200,000-30,200,000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
1
-1
0
0
0
0
0
0
0
-1
-1
0
0
1
0
0
0
1
1
11000100-1-10000000-11-1000000000000000000000000
> Total Stockholder Equity
62,409,249
62,118,141
61,538,412
70,026,936
68,845,348
64,141,022
61,165,835
55,415,123
55,397,738
54,907,842
55,060,419
54,410,255
53,673,569
53,419,887
53,724,744
52,870,789
52,687,687
52,377,793
50,362,035
51,167,279
48,225,144
46,151,776
60,446,980
56,082,999
56,647,471
57,690,882
64,350,149
62,272,436
62,074,077
61,942,799
65,912,941
63,551,209
64,133,456
69,391,634
72,028,930
65,746,493
65,660,292
70,570,180
78,249,686
125,819,596
129,298,869
132,953,987
132,685,831
127,827,372
127,827,372132,685,831132,953,987129,298,869125,819,59678,249,68670,570,18065,660,29265,746,49372,028,93069,391,63464,133,45663,551,20965,912,94161,942,79962,074,07762,272,43664,350,14957,690,88256,647,47156,082,99960,446,98046,151,77648,225,14451,167,27950,362,03552,377,79352,687,68752,870,78953,724,74453,419,88753,673,56954,410,25555,060,41954,907,84255,397,73855,415,12361,165,83564,141,02268,845,34870,026,93661,538,41262,118,14162,409,249
   Common Stock
5,500,000
5,500,000
5,500,000
5,500,000
5,500,000
5,500,000
5,500,000
5,500,000
5,500,000
5,500,000
5,500,000
5,500,000
5,500,000
5,500,000
5,500,000
5,500,000
5,500,000
5,500,000
5,500,000
5,500,000
5,500,000
5,500,000
6,500,000
6,500,000
6,500,000
6,500,000
6,500,000
6,500,000
6,500,000
6,500,000
6,694,896
6,694,896
6,694,896
6,705,431
6,768,642
6,768,642
6,768,642
6,850,823
6,850,823
6,857,225
0
0
0
0
00006,857,2256,850,8236,850,8236,768,6426,768,6426,768,6426,705,4316,694,8966,694,8966,694,8966,500,0006,500,0006,500,0006,500,0006,500,0006,500,0006,500,0006,500,0005,500,0005,500,0005,500,0005,500,0005,500,0005,500,0005,500,0005,500,0005,500,0005,500,0005,500,0005,500,0005,500,0005,500,0005,500,0005,500,0005,500,0005,500,0005,500,0005,500,0005,500,0005,500,000
   Retained Earnings Total Equity00000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 00000000000000000000000000000000000000000000
   Capital Surplus 00000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000-2,565,279-2,565,279-2,565,279-2,565,279-2,565,279-2,565,279-2,565,279-2,565,279-2,565,279-2,565,279-2,565,279-2,565,279-2,565,279-2,565,279-2,565,279-2,565,279-2,565,279-2,565,279-1,877,969-1,877,96900-1,877,969
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,799
3,799
0
3,799
3,799
-100,000
-24,766
-105,730
-293,565
-194,431
-131,820
363,765
-187,376
-3,666,616
336,538
-89,893
-1,164,093
-194,947
-158,670
1,498,202
1,419,690
2,107,288
6,062,240
13,062,816
56,018,879
0
0
0
0
000056,018,87913,062,8166,062,2402,107,2881,419,6901,498,202-158,670-194,947-1,164,093-89,893336,538-3,666,616-187,376363,765-131,820-194,431-293,565-105,730-24,766-100,0003,7993,79903,7993,799000000000000000



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue196,345,808
Cost of Revenue-122,275,013
Gross Profit74,070,79574,070,795
 
Operating Income (+$)
Gross Profit74,070,795
Operating Expense-189,874,780
Operating Income6,471,028-115,803,986
 
Operating Expense (+$)
Research Development5,600,898
Selling General Administrative31,299,092
Selling And Marketing Expenses0
Operating Expense189,874,78036,899,990
 
Net Interest Income (+$)
Interest Income33,402
Interest Expense-3,544,548
Other Finance Cost-0
Net Interest Income-3,511,146
 
Pretax Income (+$)
Operating Income6,471,028
Net Interest Income-3,511,146
Other Non-Operating Income Expenses0
Income Before Tax (EBT)1,423,7816,471,028
EBIT - interestExpense = -3,544,548
1,663,540
5,208,088
Interest Expense3,544,548
Earnings Before Interest and Taxes (EBIT)04,968,329
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax1,423,781
Tax Provision--239,758
Net Income From Continuing Ops1,663,5401,663,540
Net Income1,663,540
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net03,511,146
 

Technical Analysis of Samil Pharm
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Samil Pharm. The general trend of Samil Pharm is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Samil Pharm's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Samil Pharm.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 9,970 < 12,650.

The bearish price targets are: 8,630 > 7,510 > 7,180.

Tweet this
Samil Pharm Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Samil Pharm. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Samil Pharm Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Samil Pharm. The current macd is -170.85427712.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Samil Pharm price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Samil Pharm. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Samil Pharm price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Samil Pharm Daily Moving Average Convergence/Divergence (MACD) ChartSamil Pharm Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Samil Pharm. The current adx is 28.43.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Samil Pharm shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Samil Pharm Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Samil Pharm. The current sar is 10,614.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Samil Pharm Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Samil Pharm. The current rsi is 41.75. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Samil Pharm Daily Relative Strength Index (RSI) ChartSamil Pharm Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Samil Pharm. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Samil Pharm price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Samil Pharm Daily Stochastic Oscillator ChartSamil Pharm Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Samil Pharm. The current cci is -116.90782778.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Samil Pharm Daily Commodity Channel Index (CCI) ChartSamil Pharm Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Samil Pharm. The current cmo is -28.35966068.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Samil Pharm Daily Chande Momentum Oscillator (CMO) ChartSamil Pharm Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Samil Pharm. The current willr is -87.85046729.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Samil Pharm Daily Williams %R ChartSamil Pharm Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Samil Pharm.

Samil Pharm Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Samil Pharm. The current atr is 588.31.

Samil Pharm Daily Average True Range (ATR) ChartSamil Pharm Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Samil Pharm. The current obv is 39,933,927.

Samil Pharm Daily On-Balance Volume (OBV) ChartSamil Pharm Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Samil Pharm. The current mfi is 37.62.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Samil Pharm Daily Money Flow Index (MFI) ChartSamil Pharm Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Samil Pharm.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-19ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-22BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-27MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-22STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Samil Pharm Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Samil Pharm based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.753
Ma 20Greater thanMa 5010,260.000
Ma 50Greater thanMa 1009,660.600
Ma 100Greater thanMa 2008,607.200
OpenGreater thanClose9,260.000
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Samil Pharm with someone you think should read this too:
  • Are you bullish or bearish on Samil Pharm? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Samil Pharm? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Samil Pharm

I send you an email if I find something interesting about Samil Pharm.


Comments

How you think about this?

Leave a comment

Stay informed about Samil Pharm.

Receive notifications about Samil Pharm in your mailbox!